Clinical Trial Update: A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma [Phase 1]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 1 pharmacokinetic study of zolbetuximab (IMAB362) in Chinese patients with locally advanced unresecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Zolbetuximab (IMAB362) (zolbetuximab)

Snippet

Sponsor: Astellas Pharma China, Inc. | Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | Phase 1 | Status: COMPLETED